First reported by pharmaphorum
Obesity biotech Kalohexis files confidential IPO
Endevica spinout Kalohexis submits confidential IPO filing to develop obesity challenger to GLP-1s
From the article
Clinical-stage Kalohexis is readying a public listing to support its obesity and cancer cachexia treatments.
Continue reading on Fierce BiotechYou might also wanna read
Obesity biotech Kalohexis files confidential IPO
pharmaphorum·1d ago
Health tech companies rush to market 'GLP-1 ready' products as weight loss drug trend grows
This article from Verge's Optimizer newsletter examines how health tech companies are marketing products specifically to GLP-1 drug users (p
theverge.com·1mo agoNovo Nordisk: Wachstum im Diabetes- und Adipositasmarkt – Innovation, Kapazitäten und Pipeline-Fokus
IT BOLTWISE·11h ago
Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?
Bars·5d ago
Daily weight loss pill available in UK pharmacies from today
The Independent·3d ago
Novo Nordisk launches first GLP-1 weight loss pill Wegovy in US at lower price than injections
Novo Nordisk has launched the first pill version of its blockbuster GLP-1 weight loss drug Wegovy in the US at a significantly lower price t
theguardian.com·6mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.